JP2000509041A - 中枢神経系障害の予防及び治療のための医薬組成物 - Google Patents
中枢神経系障害の予防及び治療のための医薬組成物Info
- Publication number
- JP2000509041A JP2000509041A JP9538180A JP53818097A JP2000509041A JP 2000509041 A JP2000509041 A JP 2000509041A JP 9538180 A JP9538180 A JP 9538180A JP 53818097 A JP53818097 A JP 53818097A JP 2000509041 A JP2000509041 A JP 2000509041A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyridinyl
- amine
- compound
- penten
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.次の式で表される化合物。 (式中、Xは約−0.3〜約−0.75のシグマm価を持つことを特徴とする置換基種に 結合している窒素または炭素である。nは1、2、3、4、5、6または7である。Z’ およびZ”は各々水素、炭素原子1個〜5個を含むアルキルを表す。A,A’および A”は各々水素、炭素原子1個〜7個を含むアルキルまたはハロを表す。構造式中 の破線はC−C単結合、C−C二重結合またはC−C三重結合を表す。構造式中の破線 がC−C単結合またはC−C二重結合を表すときは、mは0または1であり、C−C三 重結合を表すときは、mは0である。構造式中の破線がC−C単結合またはC−C二 重結合を表すときは、pは0または1であり、C−C三重結合を表すときは、pは0で ある。構造式中の破線がC−C二重結合であるとき、構造式中の波線はシス(Z)形 またはトランス(E)形の化合物を表す。E’およびE”は、各々水素、炭素原子 1個〜5個を含むアルキルまたは炭素原子1個〜5個を含むハロ置換アルキルを表 す。) 2.(E)および(Z)−N−メチル−4−(3−ピリジニル)−2−メチル−3− ブテン−1−アミン、(E)および(Z)−N−メチル−4−(3−ピリジニル)−3 −メチル−3−ブテン−1−アミン、(E)および(Z)−N−メチル−6−(3−ピ リジニル)−5−ヘキセン−3−アミン、(E)および(Z)−N−メチル−5−(3 −ピリジニル)−2−メチル−4−ペンテン−2−アミン、(E)および(Z)−N− メチル−5−(3−ピリジニル)−3−メチル−4−ペンテン−2−アミン、(E)お よび(Z)−N−メチル−5−(3−ピリジニル)−4−ペンテン−2−アミン、(E )および(Z) −N−メチル−5−(3−ピリジニル)−1,1,1−トリフルオロ−4−ペンテン−1− アミン、(E)および(Z)−N−メチル−5−(3−ピリジニル)−4−メチル−4 −ペンテン−1−アミン、(E)および(Z)−N−メチル−5−(3−ピリジニル) −4−メチル−4−ペンテン−2−アミン、(E)および(Z)−N−メチル−8−(3 −ピリジニル)−7−オクテン−5−アミン、(E)および(Z)−N−メチル−7− (3−ピリジニル)−3−メチル−6−ヘプテン−4−アミン、(E)および(Z)−N −メチル−6−(3−ピリジニル)−2,4−ジメチル−5−ヘキセン−2−アミン、 (E)および(Z)−N−メチル−6−(3−ピリジニル)−5-メチル−5−ヘキセン −2−アミン、(E)および(Z)−N−メチル−6−(3−ピリジニル)−5−ヘキ セン−2−アミン、(E)および(Z)−N−メチル−6−(3−ピリジニル)−5− メチル−5−ヘキセン−3−アミン、(E)および(Z)−4−(3−ピリジニル)− 2−メチル−3−ブテン−1−アミン、(E)および(Z)−4−(3−ピリジニル) −3−メチル−3−ブテン−1−アミン、(E)および(Z)−6−(3−ピリジニル )−5−ヘキセン−3−アミン、(E)および(Z)−5−(3−ピリジニル)−2− メチル−4−ペンテン−2−アミン、(E)および(Z)−5−(3−ピリジニル)− 3−メチル−4−ペンテン−2−アミン、(E)および(Z)−5−(3−ピリジニル )−4−ペンテン−2−アミン、(E)および(Z)−5−(3−ピリジニル)−1,1, 1−トリフルオロ−4−ペンテン−2−アミン、(E)および(Z)−5−(3−ピリ ジニル)−4−メチル−4−ペンテン−1−アミン、(E)および(Z)−5−(3− ピリジニル)−4−メチル−4−ペンテン−2−アミン、(E)および(Z)−8−( 3−ピリジニル)−7−オクテン−5−アミン、(E)および(Z)−7−(3−ピリ ジニル)−3−メチル−6−ヘプテン−4−アミン、(E)および(Z)−6−(3− ピリジニル)−2,4−ジメチル−5−ヘキセン−2−アミン、(E)および(Z)−6 −(3−ピリジニル)−5−メチル−5−ヘキセン−2−アミン、(E)および(Z) −6−(3−ピリジニル)−5−ヘキセン−2−アミン、および(E)および(Z)− 6−(3−ピリジニル)−5− メチル−5−ヘキセン−3−アミンからなる群から選ばれる化合物。 3.N−メチル−4−(3−ピリジニル)−2−メチル−ブタン−1−アミン、 N−メチル−4−(3−ピリジニル)−3−メチル−ブタン−1−アミン、 N−メチル−6−(3−ピリジニル)−ヘキサン−3−アミン、 N−メチル−5−(3−ピリジニル)−2−メチル−ペンタン−2−アミン、 N−メチル−5−(3−ピリジニル)−3−メチル−ペンタン−2−アミン、 N−メチル−5−(3−ピリジニル)−ペンタン−2−アミン、 N−メチル−5−(3−ピリジニル)−1,1,1−トリフルオロ−ペンタン−2−アミ ン、 N−メチル−5−(3−ピリジニル)−4−メチル−ペンタン−1−アミン、 N−メチル−5−(3−ピリジニル)−4−メチル−ペンタン−2−アミン、 N−メチル−8−(3−ピリジニル)−オクタン−5−アミン、 N−メチル−7−(3−ピリジニル)−3−メチル−ヘプタン−4−アミン、 N−メチル−6−(3−ピリジニル)−2,4−ジメチル−ヘキサン−2−アミン、 N−メチル−6−(3−ピリジニル)−5−メチル−ヘキサン−2−アミン、 N−メチル−6−(3−ピリジニル)−ヘキサン−2−アミン、 N−メチル−6−(3−ピリジニル)−5−メチル−ヘキサン−3−アミン、 4−(3−ピリジニル)−2−メチル−ブタン−1−アミン、 4−(3−ピリジニル)−3−メチル−ブタン−1−アミン、 6−(3−ピリジニル)−ヘキサン−3−アミン、 5−(3−ピリジニル)−2−メチル−ペンタン−2−アミン、 5−(3−ピリジニル)−3−メチル−ペンタン−2−アミン、 5−(3−ピリジニル)−ペンタン−2−アミン、 5−(3−ピリジニル)−1,1,1−トリフルオロ−ペンタン−2−アミン、 5−(3−ピリジニル)−4−メチル−ペンタン−1−アミン、 5−(3−ピリジニル)−4−メチル−ペンタン−2−アミン、 8−(3−ピリジニル)−オクタン−5−アミン、 7−(3−ピリジニル)−3−メチル−ヘプタン−4−アミン、 6−(3−ピリジニル)−2,4−ジメチル−ヘキサン−2−アミン、 6−(3−ピリジニル)−5−メチル−ヘキサン−2−アミン、 6−(3−ピリジニル)−ヘキサン−2−アミン、および 6−(3−ピリジニル)−5−メチル−ヘキサン−3−アミン からなる群から選ばれる化合物。 4.N−メチル−5−(3−ピリジニル)−4−ペンチン−2−アミン、 N−メチル−6−(3−ピリジニル)−5−ヘキシン−3−アミン、 N−メチル−7−(3−ピリジニル)−6−ヘプチン−4−アミン、 N−メチル−8−(3−ピリジニル)−7−オクチン−5−アミン、 N−メチル−9−(3−ピリジニル)−8−ノニン−6−アミン、 N−メチル−5−(3−ピリジニル)−3−メチル−4−ペンチン−2−アミン、 5−(3−ピリジニル)−4−ペンチン−2−アミン、 6−(3−ピリジニル)−5−ヘキシン−3−アミン、 7−(3−ピリジニル)−6−ヘプチン−4−アミン、 8−(3−ピリジニル)−7−オクチン−5−アミン、 9−(3−ピリジニル)−8−ノニン−6−アミンおよび 5−(3−ピリジニル)−3−メチル−4−ペンチン−2−アミン からなる群から選ばれる化合物。 5.波線がC−C二重結合であって、化合物がトランス(E)形である請求項1 に記載の化合物。 6.nが1、2、3または4である請求項1に記載の化合物。 7.nが1、2または3であり、Z’およびZ”が各々水素、メチルまたはイソ プロピルを表し、AおよびA’は水素を表し、ならびに、A”は水素、メチル、エ チルまたはハロを表す請求項1に記載の化合物。 8.波線がC−C二重結合であって、化合物がトランス(E)形である請求項7 に記載の化合物。 9.Xが−CHである請求項1に記載の化合物。 10.A、A’およびA”各々が水素である請求項6に記載の化合物。 11.E’およびE”がメチルである請求項1に記載の化合物。 12.m=0およびp=0である請求項1に記載の化合物。 13.Z’は水素であり、Z”はメチルである請求項1に記載の化合物。 14.nが2または3である請求項1に記載の化合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63176196A | 1996-04-23 | 1996-04-23 | |
US08/631,761 | 1996-04-23 | ||
PCT/US1997/006398 WO1997040011A1 (en) | 1996-04-23 | 1997-04-16 | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008060649A Division JP2008247903A (ja) | 1996-04-23 | 2008-03-11 | 中枢神経系障害の予防及び治療のための医薬組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2000509041A true JP2000509041A (ja) | 2000-07-18 |
JP2000509041A5 JP2000509041A5 (ja) | 2005-12-08 |
JP4357001B2 JP4357001B2 (ja) | 2009-11-04 |
Family
ID=24532629
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53818097A Expired - Fee Related JP4357001B2 (ja) | 1996-04-23 | 1997-04-16 | 中枢神経系障害の予防及び治療のための医薬組成物 |
JP2008060649A Pending JP2008247903A (ja) | 1996-04-23 | 2008-03-11 | 中枢神経系障害の予防及び治療のための医薬組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008060649A Pending JP2008247903A (ja) | 1996-04-23 | 2008-03-11 | 中枢神経系障害の予防及び治療のための医薬組成物 |
Country Status (12)
Country | Link |
---|---|
US (2) | US6603011B1 (ja) |
EP (2) | EP1997806A1 (ja) |
JP (2) | JP4357001B2 (ja) |
AT (1) | ATE416164T1 (ja) |
AU (1) | AU727976B2 (ja) |
BR (1) | BR9708815B1 (ja) |
CA (1) | CA2252515C (ja) |
DE (1) | DE69739142D1 (ja) |
DK (1) | DK0900200T5 (ja) |
ES (1) | ES2318856T4 (ja) |
PT (1) | PT900200E (ja) |
WO (1) | WO1997040011A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006511482A (ja) * | 2002-10-02 | 2006-04-06 | ターガセプト,インコーポレイテッド | コリン作動性受容体を活性化できる化合物 |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6166048A (en) * | 1999-04-20 | 2000-12-26 | Targacept, Inc. | Pharmaceutical compositions for inhibition of cytokine production and secretion |
US20020052497A1 (en) | 2000-03-09 | 2002-05-02 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
KR20010052171A (ko) | 1998-04-02 | 2001-06-25 | 알. 제이. 레이놀즈 터베코 컴퍼니 | 의약 조성물 및 그 사용방법 |
US7790757B2 (en) | 1998-06-16 | 2010-09-07 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
US6232316B1 (en) | 1998-06-16 | 2001-05-15 | Targacept, Inc. | Methods for treatment of CNS disorders |
US20050131034A1 (en) * | 1998-06-16 | 2005-06-16 | Caldwell William S. | Compounds capable of activating cholinergic receptors |
ES2228054T3 (es) * | 1998-06-16 | 2005-04-01 | Targacept, Inc. | Aminas olefinicas sustituidas con arilo y su uso como agonistas de receptores colinergicos. |
US6455734B1 (en) | 2000-08-09 | 2002-09-24 | Magnesium Diagnostics, Inc. | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
AU2005201609B2 (en) * | 1999-04-20 | 2007-10-18 | Targacept, Inc | Pharmaceutical compositions for inhibition of cytokine production and secretion |
US20010031771A1 (en) | 1999-05-24 | 2001-10-18 | Gary Maurice Dull | Pharmaceutical compositions and methods for use |
AU5326100A (en) * | 1999-06-07 | 2000-12-28 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
MXPA02001095A (es) * | 1999-07-30 | 2002-08-20 | Vertex Pharma | Derivados de amina ciclicos y aciclicos. |
WO2001082978A2 (en) * | 2000-05-01 | 2001-11-08 | Targacept, Inc. | Imaging of nicotinic acetylcholine receptor subtypes |
FR2838436A1 (fr) * | 2002-04-16 | 2003-10-17 | Rhodia Chimie Sa | Composes amines porteurs d'au moins un allyle et d'un difluoromethyle et procede utile a leur synthese |
EP1494994A2 (fr) * | 2002-04-16 | 2005-01-12 | Rhodia Chimie | Composes amines porteurs d'au moins un allyle et d'un difluoromethyle et procede utile a leur synthese |
FR2847578A1 (fr) * | 2002-11-21 | 2004-05-28 | Rhodia Chimie Sa | Composes amines porteurs d'au moins un allyle et d'un difluoromethyle et procede utile a leur synthese |
US7731740B2 (en) * | 2004-04-02 | 2010-06-08 | Arterial Remodelling Technologies, Inc. | Polymer-based stent assembly |
US7459469B2 (en) | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
UA88792C2 (ru) | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Гидроксибензоатные соли метаникотиновых соединений |
CN101528698A (zh) | 2006-05-09 | 2009-09-09 | 阿斯利康公司 | (2s)-(4e)-n-甲基-5-[3-(5-异丙氧基吡啶)基]-4-戊烯-2-胺的盐形式 |
TWI389889B (zh) * | 2006-05-09 | 2013-03-21 | Targacept Inc | (2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型 |
AR062860A1 (es) * | 2006-09-15 | 2008-12-10 | Astrazeneca Ab | Combinaciones terapeuticas 482 |
US20100028447A1 (en) * | 2007-01-22 | 2010-02-04 | Targacept, Inc. | Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs |
EP2647373A1 (en) | 2008-05-12 | 2013-10-09 | Targacept, Inc. | Methods for preventing the development of retinopathy by the oral administration of exo-S-mecamylamine. |
WO2010080757A2 (en) | 2009-01-07 | 2010-07-15 | Astrazeneca Ab | Combinations with an alpha-4beta-2 nicotinic agonist |
WO2011146009A1 (en) | 2010-05-20 | 2011-11-24 | Targacept Inc. | New process for the preparation of aryl substituted olefinic amines |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4965074A (en) | 1985-03-05 | 1990-10-23 | Ciba-Geigy Corporation | Method of treating memory impairment |
US4684654A (en) * | 1985-08-14 | 1987-08-04 | American Cyanamid Company | 3-heteroalkyl-2,4-quinzaolinediones |
US4788206A (en) * | 1987-07-10 | 1988-11-29 | Hoffmann-La Roche Inc. | Pentadieneamides |
US4927838A (en) * | 1987-07-10 | 1990-05-22 | Hoffman-La Roche Inc. | Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors |
US4786646A (en) * | 1987-07-10 | 1988-11-22 | Hoffmann-La Roche Inc. | Cyclopropylpropenamides |
US4922901A (en) | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
US5210076A (en) | 1988-09-13 | 1993-05-11 | Berliner David L | Methods of treating Parkinson's disease using melanin |
US5356906A (en) | 1989-10-27 | 1994-10-18 | The Du Pont Merck Pharmaceutical Company | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis |
DE4102289A1 (de) | 1991-01-26 | 1992-07-30 | Bayer Ag | Verfahren zur herstellung von (hetero)arylalk(en/in)-ylaminen und neue (hetero)arylkinylamine |
DK0588917T3 (da) | 1991-05-29 | 2001-02-12 | Abbott Lab | Isoxazol- og isothiazolforbindelser, som forstærker kognitiv funktion |
US5212188A (en) | 1992-03-02 | 1993-05-18 | R. J. Reynolds Tabacco Company | Method for treatment of neurodegenerative diseases |
US5242935A (en) | 1992-03-06 | 1993-09-07 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
US5227391A (en) | 1992-04-10 | 1993-07-13 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
US5723477A (en) | 1994-11-10 | 1998-03-03 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
US5616707A (en) | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
AU4610896A (en) * | 1995-01-06 | 1996-07-24 | R.J. Reynolds Tobacco Company | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
US5597919A (en) | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
US5616716A (en) * | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
-
1997
- 1997-04-16 EP EP08014695A patent/EP1997806A1/en not_active Withdrawn
- 1997-04-16 AT AT97921232T patent/ATE416164T1/de active
- 1997-04-16 EP EP97921232A patent/EP0900200B9/en not_active Expired - Lifetime
- 1997-04-16 WO PCT/US1997/006398 patent/WO1997040011A1/en active IP Right Grant
- 1997-04-16 ES ES97921232T patent/ES2318856T4/es not_active Expired - Lifetime
- 1997-04-16 PT PT97921232T patent/PT900200E/pt unknown
- 1997-04-16 BR BRPI9708815-3A patent/BR9708815B1/pt not_active IP Right Cessation
- 1997-04-16 DK DK97921232T patent/DK0900200T5/da active
- 1997-04-16 AU AU27332/97A patent/AU727976B2/en not_active Ceased
- 1997-04-16 DE DE69739142T patent/DE69739142D1/de not_active Expired - Lifetime
- 1997-04-16 CA CA002252515A patent/CA2252515C/en not_active Expired - Fee Related
- 1997-04-16 JP JP53818097A patent/JP4357001B2/ja not_active Expired - Fee Related
-
2000
- 2000-08-21 US US09/642,351 patent/US6603011B1/en not_active Expired - Fee Related
-
2001
- 2001-10-09 US US09/973,419 patent/US6555684B2/en not_active Expired - Fee Related
-
2008
- 2008-03-11 JP JP2008060649A patent/JP2008247903A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006511482A (ja) * | 2002-10-02 | 2006-04-06 | ターガセプト,インコーポレイテッド | コリン作動性受容体を活性化できる化合物 |
Also Published As
Publication number | Publication date |
---|---|
CA2252515A1 (en) | 1997-10-30 |
EP1997806A1 (en) | 2008-12-03 |
WO1997040011A1 (en) | 1997-10-30 |
BR9708815B1 (pt) | 2009-01-13 |
BR9708815A (pt) | 2000-01-04 |
JP4357001B2 (ja) | 2009-11-04 |
ATE416164T1 (de) | 2008-12-15 |
PT900200E (pt) | 2009-02-26 |
US6603011B1 (en) | 2003-08-05 |
EP0900200B9 (en) | 2009-10-21 |
EP0900200A1 (en) | 1999-03-10 |
DK0900200T5 (da) | 2010-01-11 |
AU2733297A (en) | 1997-11-12 |
AU727976B2 (en) | 2001-01-04 |
JP2008247903A (ja) | 2008-10-16 |
ES2318856T3 (es) | 2009-05-01 |
EP0900200B1 (en) | 2008-12-03 |
DE69739142D1 (de) | 2009-01-15 |
ES2318856T4 (es) | 2010-03-03 |
US6555684B2 (en) | 2003-04-29 |
DK0900200T3 (da) | 2009-03-30 |
CA2252515C (en) | 2006-11-07 |
US20020032206A1 (en) | 2002-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000509041A (ja) | 中枢神経系障害の予防及び治療のための医薬組成物 | |
US5616716A (en) | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds | |
US5616707A (en) | Compounds which are useful for prevention and treatment of central nervous system disorders | |
US5597919A (en) | Pyrimidinyl or Pyridinyl alkenyl amine compounds | |
US6492399B1 (en) | Pharmaceutical compositions and methods for use | |
KR100593433B1 (ko) | 아릴 치환된 올레핀계 아민 및 콜린성 수용체 작용제로서의 그들의 용도 | |
US6455554B1 (en) | Oxopyridinyl pharmaceutical compositions and methods for use | |
US5824692A (en) | Pharmaceutical compositions for prevention and treatment of central nervous system disorders | |
JP2011144192A (ja) | コリン作動性受容体を活性化できる化合物 | |
US5731314A (en) | Pharamceutical compositions for prevention and treatment of tourette's syndrome | |
EP0801527B1 (en) | Pharmaceutical compositions for prevention and treatment of central nervous system disorders | |
US7060826B2 (en) | Compounds capable of activating cholinergic receptors | |
KR100572189B1 (ko) | 아릴 치환된 올레핀계 아민 화합물을 혼합한 약학 조성물 | |
KR100568997B1 (ko) | 중추신경계질환의예방및치료를위한약제학적조성물 | |
US20030087915A1 (en) | Pharmaceutical compositions and methods for use | |
MXPA00012858A (en) | Aryl substituted olefinic amines and their use as cholinergic receptors agonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040127 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20040921 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050520 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070911 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20070904 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071210 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080311 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080311 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080408 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080603 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080901 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090721 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090804 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120814 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130814 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |